1. An exploratory phase II study of Eribulin re-challenge after short term therapy of 5-fuluorouracil for HER2-negative, advanced or recurrent breast cancer
- Author
-
Kosei Hirakawa, Shinzoh Kudoh, Minoru Takada, Satoru Noda, Naoyoshi Onoda, Yoshinari Ogawa, Takeo Nishimori, Hidemi Kawajiri, Katsumi Ikeda, Tetsuro Ishikawa, Yoko Mizuyama, Tsutomu Takashima, Masaichi Ohira, Shigehito Yamagata, Seika Tei, Shinya Tokunaga, Kenji Tezuka, Shinichiro Kashiwagi, Takeshi Sunami, and Shigehiko Nishimura
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,Receptor, ErbB-2 ,medicine.medical_treatment ,Breast Neoplasms ,Exploratory phase ,chemistry.chemical_compound ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,Humans ,Medicine ,Re challenge ,Adverse effect ,Furans ,neoplasms ,Recurrent breast cancer ,Aged ,Chemotherapy ,business.industry ,Incidence (epidemiology) ,HER2 negative ,General Medicine ,Ketones ,Middle Aged ,medicine.disease ,Prognosis ,Metastatic breast cancer ,Short term therapy ,Survival Rate ,chemistry ,Fluorouracil ,Retreatment ,Female ,Neoplasm Recurrence, Local ,business ,medicine.drug ,Follow-Up Studies ,Eribulin - Abstract
Background/aim In our previous study, first-line eribulin (ERI) showed 25 weeks of progression-free survival (PFS). This study investigated the efficacy and safety of ERI re-administration in metastatic breast cancer (MBC) patients. Patients and methods HER2-negative MBC patients who had never received chemotherapy for MBC received first-line ERI for 18 weeks if they did not have disease progression, and then one cycle of S-1 before ERI re-administration. Results Twelve patients received ERI re-administration. The PFS of re-administered ERI was 13 weeks. Total duration of ERI use was 30 weeks. The incidence and severity of adverse events were consistent with previous reports. Conclusion In the first-line setting, the total PFS of eribulin was extended by S-1 administration before disease progression, compared with that of our previous report.
- Published
- 2020
- Full Text
- View/download PDF